Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes

A Phase Ib, Randomized, Open-Label, Multi-Center, 4-Week Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITCA 650 in Subjects With Type 2 Diabetes Mellitus

evaluate the safety and tolerability of ITCA 650 in subjects with type 2 diabetes mellitus.

Inclusion Criteria:

• type 2 diabetes >6 months
• stable diet & exercise, metformin, TZD or met + TZD HbA1c >6.5% <10.0%

Exclusion Criteria:

• prior treatment with exenatide
• history of pancreatitis
• history of medullary thyroid cancer or multiple endocrine neoplasia 2